文献速递肝病

奥贝胆酸治疗原发性胆汁性胆管炎的长期临床影响与成本效果

Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.
PubMed 文献 · Hepatology · 2017-01-17

研究建立数学模型模拟原发性胆汁性胆管炎患者终身病程,比较奥贝胆酸联合熊去氧胆酸与单用熊去氧胆酸。联合治疗可降低15年失代偿肝硬化、肝细胞癌、肝移植和肝病死亡累积发生率并提高无移植生存率,但终身费用大幅增加,增量成本效果比为每获得一个质量调整生命年473,400美元,以100,000美元/质量调整生命年支付阈值判断不具成本效果。

要点

  • 奥贝胆酸联合熊去氧胆酸较单用熊去氧胆酸降低15年失代偿肝硬化累积发生率(12.2%降至4.5%)
  • 联合治疗提高15年无移植生存率(61.1%升至72.9%),但终身费用从63,000美元增至902,000美元
  • 以100,000美元/质量调整生命年支付阈值,奥贝胆酸不具成本效果,需年定价低于18,450美元

核心结论

  • 奥贝胆酸是有望显著改善原发性胆汁性胆管炎患者长期结局的新疗法,但按当前年定价69,350美元,以100,000美元/质量调整生命年支付阈值判断不具成本效果,年定价需低于18,450美元才具成本效果。

研究设计与样本

  • 建立数学模型模拟原发性胆汁性胆管炎患者终身病程,比较奥贝胆酸联合熊去氧胆酸与单用熊去氧胆酸。
  • 疗效数据来自3期PBC OCA International Study of Efficacy试验,自然史依据已发表临床研究,模型结局用PBC Global Study验证。

主要发现

  • 与单用熊去氧胆酸相比,奥贝胆酸联合熊去氧胆酸使15年失代偿肝硬化累积发生率从12.2%降至4.5%。
  • 联合治疗使15年肝细胞癌累积发生率从9.1%降至4.0%,肝移植从4.5%降至1.2%,肝病死亡从16.2%降至5.7%。
  • 联合治疗使15年无移植生存率从61.1%升至72.9%。
  • 原发性胆汁性胆管炎终身治疗费用从63,000美元增至902,000美元(增幅1,330%)。
  • 单用熊去氧胆酸与联合治疗的贴现质量调整生命年分别为10.74和11.78,对应费用分别为142,300美元和633,900美元,增量成本效果比为每获得一个质量调整生命年473,400美元。

关键数值与推荐

  • 结果对奥贝胆酸成本最为敏感。
  • 奥贝胆酸当前年定价为69,350美元。
  • 以100,000美元/质量调整生命年支付阈值判断不具成本效果,年定价需低于18,450美元才具成本效果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Primary biliary cholangitis (PBC) is a chronic, progressive autoimmune liver disease that mainly affects middle-aged women. Obeticholic acid (OCA), which was recently approved by the Food and Drug Administration for PBC treatment, has demonstrated positive effects on biochemical markers of liver function. Our objective was to evaluate the long-term clinical impact and cost-effectiveness of OCA as a second-line treatment for PBC in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA. We developed a mathematical model to simulate the lifetime course of PBC patients treated with OCA+UDCA versus UDCA alone. Efficacy data were derived from the phase 3 PBC OCA International Study of Efficacy trial, and the natural history of PBC was informed by published clinical studies. Model outcomes were validated using the PBC Global Study. We found that in comparison with UDCA, OCA+UDCA could decrease the 15-year cumulative incidences of decompensated cirrhosis from 12.2% to 4.5%, hepatocellular carcinoma from 9.1% to 4.0%, liver transplants from 4.5% to 1.2%, and liver-related deaths from 16.2% to 5.7% and increase 15-year transplant-free survival from 61.1% to 72.9%. The lifetime cost of PBC treatment would increase from $63,000 to $902,000 (1,330% increment). The discounted quality-adjusted life years with UDCA and OCA+UDCA were 10.74 and 11.78, respectively, and the corresponding costs were $142,300 and $633,900, resulting in an incremental cost-effectiveness ratio of $473,400/quality-adjusted life year gained. The results were most sensitive to the cost of OCA. CONCLUSION: OCA is a promising new therapy to substantially improve the long-term outcomes of PBC patients, but at its current annual price of $69,350, it is not cost-effective using a willingness-to-pay threshold of $100,000/quality-adjusted life year; pricing below $18,450/year is needed to make OCA cost-effective. (Hepatology 2017;65:920-928).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Samur S, Klebanoff M, Banken R, et al. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis. Hepatology. 2017. PMID: 27906472. doi:10.1002/hep.28932

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。